Hiroshi Ikegami
Overview
Explore the profile of Hiroshi Ikegami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
2755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Babaya N, Yoshida S, Noso S, Hiromine Y, Taketomo Y, Kimura T, et al.
Am J Case Rep
. 2025 Mar;
26:e946022.
PMID: 40057822
BACKGROUND Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell non-Hodgkin's lymphoma. Autoimmune (Hashimoto's) thyroiditis is associated with thyroid MALT lymphoma, but co-existence with papillary thyroid carcinoma (PTC) has been...
2.
Ebisuno T, Tachibana M, Imagawa A, Kanatsuna N, Terasaki J, Abiru N, et al.
Diabetol Int
. 2025 Jan;
16(1):39-49.
PMID: 39877451
Introduction: Type 1 diabetes is often accompanied by autoimmune thyroid disease. We aimed to investigate the clinical characteristics of Japanese patients with acute-onset type 1 diabetes and thyroid autoantibodies, focusing...
3.
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, et al.
Diabetol Int
. 2025 Jan;
16(1):1-6.
PMID: 39877440
Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are...
4.
Miyasaka Y, Maegawa T, Nagura T, Kobayashi M, Babaya N, Ikegami H, et al.
Exp Anim
. 2024 Dec;
PMID: 39721698
Streptozotocin (STZ) is widely used as a pancreatic beta-cell toxin to induce experimental diabetes in rodents. Strain-dependent variations in STZ-induced diabetes susceptibility have been reported in mice. Differences in STZ-induced...
5.
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, et al.
J Diabetes Investig
. 2024 Nov;
16(1):163-168.
PMID: 39529490
Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are...
6.
Ikegami H, Noso S
Diabetol Int
. 2024 Oct;
15(4):688-698.
PMID: 39469551
Type-1 diabetes is a multifactorial disease characterized by genetic and environmental factors that contribute to its development and progression. Despite progress in the management of type-1 diabetes, the final goal...
7.
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, et al.
Diabetol Int
. 2024 Aug;
15(3):638-639.
PMID: 39101174
[This corrects the article DOI: 10.1007/s13340-023-00679-1.].
8.
Nishimura R, Shimada A, Abiru N, Matsuhisa M, Takahashi Y, Ikegami H
Diabetol Int
. 2024 Mar;
15(2):212-222.
PMID: 38524926
Aims/introduction: Psychosocial aspects and the quality of life (QOL) of individuals with diabetes are important for achieving glycemic control and treatment goals. Here, we describe patient-reported outcomes (PROs) of Japanese...
9.
Kawasaki E, Awata T, Ikegami H, Imagawa A, Oikawa Y, Osawa H, et al.
J Diabetes Investig
. 2024 Mar;
15(7):835-842.
PMID: 38451108
Aims/introduction: This study aimed to identify risk factors that contribute to the progression of slowly-progressive type 1 diabetes by evaluating the positive predictive value (PPV) of factors associated with the...
10.
Babaya N, Noso S, Hiromine Y, Taketomo Y, Niwano F, Yoshida S, et al.
Sci Rep
. 2024 Mar;
14(1):5099.
PMID: 38429333
Continuous glucose monitoring (CGM) values obtained from CGM systems using the same sensor but with different internal algorithms (the first- and third-generation FreeStyle Libre (1st-gen-libre and 3rd-gen-libre, respectively)) were compared....